Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an Indian listed company in the Pharmaceuticals & Biotechnology industry (Healthcare sector), traded under NSE: GLENMARK and BSE: 532296 (ISIN INE935A01035).
It has a market capitalisation of ₹62,372 crore, a last close of ₹2,210 on 2026-10-19, a one-year return of 18.7%.
Valuation: a price-to-earnings ratio of 41.68x, a price-to-book ratio of 5.93x, a dividend yield of 0.1%.
Profitability: return on equity of 0.0%, return on capital employed of 18.6%, an operating margin of 27.0%.
Growth: sales growth of 9.3% a year over three years.
Balance sheet and ownership: debt-to-equity of 0.00x, promoter holding of 46.7%.
| Metric | Value |
|---|---|
| Market capitalisation | 62,372 |
| Last close | ₹2,210 |
| P/E (TTM) | 41.68x |
| P/B | 5.93x |
| Dividend yield | 0.1% |
| ROE (FY) | 0.0% |
| ROCE (FY) | 18.6% |
| Operating margin (TTM) | 27.0% |
| Sales growth, 3-year CAGR | 9.3% |
| Debt / equity | 0.00x |
| Promoter holding | 46.7% |
| 1-year return | 18.7% |
Loading the live page with the price chart, financial history, shareholding and recent filings. Data is end-of-day and rebuilt nightly; nothing here is investment advice. Financial statements · What each metric means